During a Case-Based Roundtable® event, Nitin Jain, MD, and participants discussed treating a patient with CLL after ...

Although CAR T-cell therapies have been found effective against certain difficult-to-treat malignancies, they are not devoid of safety concerns.

NEW YORK - IN8bio, Inc. (Nasdaq: INAB), a biopharmaceutical company specializing in gamma-delta T cell therapies with a current market capitalization of $23.42 million, has announced encouraging Phase ...

Two months after Allogene abandoned plans for its CAR-T in leukemia, analysts have suggested that fresh phase 1 data in ...

IN8bio is accelerating patient enrollment in the INB-100 program and expects to complete enrollment of the expansion cohort in 2025. The company’s FDA discussions confirmed that relapse-free survival ...

IN8bio (INAB) presented Phase 1 data on its allogeneic gamma-delta T cell therapy, INB-100, at the 2025 Transplantation & Cellular Therapy, ...

A new international study has found that a simple tablet treatment could improve survival rates for people with chronic ...

Unrelated cord blood transplant demonstrated efficacy in patients with blood cancer after microcystic adnexal carcinoma.

Scientists at the Garvan Institute of Medical Research have discovered that certain gene variations associated with leukemia ...

Researchers at the LKS Faculty of Medicine of the University of Hong Kong (HKUMed) have invented an oral formulation of ...

Provider prioritization of relationship-building alongside explanations could foster trust and facilitate open information exchange, supporting informed decisions,” researchers wrote.

Members of the Leukemia and Lymphoma Society discussed the importance of educating others, fundraising and spreading ...